Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 18.68
-0.691 %
$ 1.09 B
Market Cap
13.94
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Embecta Corp.
| Net Income | 78.3 M |
| Depreciation & Amortization | 36.2 M |
| Capital Expenditures | -15.8 M |
| Stock-Based Compensation | 26.3 M |
| Change in Working Capital | -47.7 M |
| Others | 96.7 M |
| Free Cash Flow | 19.9 M |
Cash Flow
Millions
| Sep-2024 | Sep-2023 | Sep-2022 | Sep-2021 | Sep-2020 | Sep-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | 78.3 | 70.4 | 223.6 | 415.0 | 427.6 | 432.0 |
| Depreciation & Amortization | 36.2 | 32.6 | 31.7 | 38.0 | 38.3 | 36.0 |
| Deferred Income Tax | (70.6) | 14.3 | (26.5) | (2.0) | (2.2) | (6.0) |
| Stock Based Compensation | 26.3 | 21.5 | 18.7 | 12.8 | 12.7 | 12.0 |
| Other Operating Activities | 13.2 | 8.9 | 72.3 | 24.0 | 9.4 | 9.0 |
| Change in Working Capital | (47.7) | (80.0) | 92.4 | (32.0) | 12.7 | 22.0 |
| Cash From Operations | 35.7 | 67.7 | 412.2 | 456.0 | 498.5 | 505.0 |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (15.8) | (26.5) | (24.0) | (39.0) | (41.9) | (69.0) |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (15.8) | (26.5) | (24.0) | (39.0) | (41.9) | (69.0) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | (3.6) | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (35.9) | (10.7) | 1 437.8 | 0 | 0 | 0 |
| Dividends Paid | (34.5) | (34.4) | (8.6) | 0 | 0 | 0 |
| Other Financing Activities | (3.0) | (3.6) | (1 477.2) | (417.1) | (456.6) | (436.0) |
| Cash From Financing Activities | (73.4) | (48.7) | (48.0) | (417.0) | (456.6) | (436.0) |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (52.3) | (4.4) | 330.9 | 0 | 0 | 0 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | 19.9 | 41.2 | 388.2 | 417.0 | 456.6 | 436.0 |